Empagliflozin/metformin fixed-dose combination: a review in patients with type 2 diabetes

References

• American Diabetes Association. Standards of medical care in diabetes-2015. Diabetes Care. 2015;38(Suppl. 1):S1–S49.
   PubMed Web of Science ®Google Scholar
• Tropeano AI. Mechanism of diabetic complications: “therapeutic” perspectives. Ann Endocrinol (Paris). 2003;64(6):474–476.
   PubMedGoogle Scholar
• CDC, Department of Health and Human Services [homepage on the Internet]. National diabetes statistics report, 2014. [updated 2014; cited May 15, 2015]. Available from: http://www.cdc.gov//diabetes/pubs/statsreport14/national-diabetes-report-web.pdf. cited 13 Jun, 2014
   Google Scholar
• Starner CI, Schafer JA, Heaton AH, et al. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events. J Manag Care Pharm. 2008;14(6):523–531.
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986.
   PubMed Web of Science ®Google Scholar
• Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373:1765–1772.
   PubMed Web of Science ®Google Scholar
• Ismail-Beigi F. Glycemic management of type 2 diabetes mellitus. N Engl J Med. 2012;366:1319–1327.
   PubMed Web of Science ®Google Scholar
• Jahagirdar V, Barnett AH. Empagliflozin for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2014;15(16):2429–2441.
   PubMed Web of Science ®Google Scholar
• SYNJARDY® (empagliflozin and metformin) label. US Food and Drug Administration, August 2015. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206111lbl.pdf. cited 2016 Jun 13.
   Google Scholar
• Hadjadj S, Rosenstock J, Meinicke T, et al. Initial combination of empagliflozin and metformin in patients with type 2 diabetes. Diabetes Care. 2016;39(10):1718–1728.
   PubMed Web of Science ®Google Scholar
• Papanas N, Maltezos E, Mikhailidis DP. Metformin: diamonds are forever. Expert Opin Pharmacother. 2009 Oct;10(15):2395–2397.
   PubMed Web of Science ®Google Scholar
• JARDIANCE® (empagliflozin). US Food and Drug Administration, 2014. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204629s000lbl.pdf. Accessed 13 Jun 2015.
   Google Scholar
• Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 1996;30(5):359–371.
   PubMed Web of Science ®Google Scholar
• Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes–causes, effects and coping strategies. Diabetes Obes Metab. 2007;9:799–812.
   PubMed Web of Science ®Google Scholar
• Hundal RS, Krssak M, Dufour S, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes. 2000;49:2063–2069.
   PubMed Web of Science ®Google Scholar
• Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012;14(1):83–90.
   PubMed Web of Science ®Google Scholar
• Sarashina A, Koiwai K, Seman LJ, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects. Drug Metab Pharmacokinet. 2013;28(3):213–219.
   PubMed Web of Science ®Google Scholar
• Heise T, Seewaldt-Becker E, Macha S, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks’ treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15(7):613–621.
   PubMed Web of Science ®Google Scholar
• NCT02702011. Empa Add on to Insulin in Japanese Patient With Type 1 Diabetes Mellitus. Available from: https://clinicaltrials.gov/ct2/show/NCT02702011. cited Jun 2016 13
   Google Scholar
• NCT01969747. Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days. Available from: https://clinicaltrials.gov/ct2/show/NCT01969747. cited 2016 Jun 13
   Google Scholar
• NCT02414958. Empagliflozin as Adjunctive to inSulin thErapy in Type 1 Diabetes Over 52 Weeks (EASE-2). Available from: https://clinicaltrials.gov/ct2/show/NCT02414958. cited Jun 2016. 13
   Google Scholar
• Perkins BA, Cherney DZ, Partridge H, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care. 2014;37(5):1480–1483.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–1379.
   PubMed Web of Science ®Google Scholar
• Giannarelli R, Aragona M, Coppelli A, et al. Reducing insulin resistance with metformin: the evidence today. Diabetes Metab. 2003;29(4 pt 2):S28–S35.
   Google Scholar
• Reynolds JK. Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes. Diabetes Metab Syn Obes Targ Ther. 2009;2:127–134.
   PubMedGoogle Scholar
• Rojas C, Link J, Meinicke T, et al. Pharmacokinetics of fixed-dose combinations of empagliflozin/metformin compared with individual tablets in healthy subjects. Int J Clin Pharmacol Ther. 2016;54(4):282–292.
   PubMed Web of Science ®Google Scholar
• Häring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2013;36(11):3396–3404.
   PubMed Web of Science ®Google Scholar
• Merker L, Häring HU, Christiansen AV, et al. Empagliflozin as add-on to metformin in people with type 2 diabetes. Diabet Med. 2015;32(12):1555–1567.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Seman LJ, Jelaska A, et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab. 2013;15(12):1154–1160.
   PubMed Web of Science ®Google Scholar
• Kovacs CS, Seshiah V, Merker L, et al. Empagliflozin as add-on therapy to pioglitazone with or without metformin in patients with type 2 diabetes mellitus. Clin Ther. 2015;37(8):1773–1788.
   PubMed Web of Science ®Google Scholar
• Ridderstrale M, Andersen KR, Zeller C, et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2:691–700.
   PubMed Web of Science ®Google Scholar
• Chen G, McAlister FA, Walker RL, et al. Cardiovascular outcomes in framingham participants with diabetes: the importance of blood pressure. Hypertension. 2011;57:891–897.
   PubMed Web of Science ®Google Scholar
• Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT study group. Lancet. 1998;351:1755–1762.
   PubMed Web of Science ®Google Scholar
• Ryden L, Grant PJ, Anker SD, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013;34:3035–3087.
   PubMed Web of Science ®Google Scholar
• Lajara R. The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. Expert Opin Pharmacother. 2014;15(17):2565–2585.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Jelaska A, Zeller C, et al. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2015;17(10):936–948.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
   PubMed Web of Science ®Google Scholar
• Zhong X, Lai D, Ye Y, et al. Efficacy and safety of empagliflozin as add-on to metformin for type 2 diabetes: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2016;72(6):655–663.
   PubMed Web of Science ®Google Scholar
• Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–334.
   PubMed Web of Science ®Google Scholar
• Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J. 2016;37(19):1526–1534.
   PubMed Web of Science ®Google Scholar
• Lee CM, Woodward M, Colagiuri S. Triple therapy combinations for the treatment of type 2 diabetes - A network meta-analysis. Diabetes Res Clin Pract. 2016;116:149–158.
   PubMed Web of Science ®Google Scholar
• Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38(9):1687–1693.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA drug safety communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood [Internet], 2015 May 15. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm. Accessed 13 Jun 2016
   Google Scholar
• Tang H, Li D, Wang T, et al. Effect of sodium-glucose cotransporter 2 inhibitors on diabetic ketoacidosis among patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Care. 2016;39(8):e123–4.
   PubMed Web of Science ®Google Scholar
• Clar C, Gill JA, Court R, et al. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open. 2012;2:5.
   Web of Science ®Google Scholar
• Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013;15(10):938–953.
   PubMed Web of Science ®Google Scholar
• Stein SA, Lamos EM, Davis SN. A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf. 2013 Mar;12(2):153–175.
   PubMed Web of Science ®Google Scholar
• Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713–719.
   PubMed Web of Science ®Google Scholar
• Hutchins V, Zhang B, Fleurence RL, et al. A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr Med Res Opin. 2011;27(6):1157–1168.
   PubMed Web of Science ®Google Scholar